Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis

Executive Summary

Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.

You may also be interested in...



AbbVie May Be Poised For An Oral RA Smack Down

Upadacitinib hit the primary endpoints in the first of six Phase III studies in rheumatoid arthritis, as well as several important secondary endpoints. Continued success in Phase III will position the candidate well in the race to market with Lilly.

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Window Shopping: Rheumatoid Arthritis Biosimilars On Show At ACR

Clinicians in the US can’t buy in to anti-TNF biosimilars yet, but wave of equivalence data featured at American College of Rheumatology meeting gives them a chance to evaluate products before they hit the market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel